Lymphoma, Mantle-Cell
Showing 26 - 50 of >10,000
Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing
Recruiting
- Relapsed or Refractory B-cell Lymphoma
- +6 more
-
Beijing, ChinaBeijing Cancer Hospital
Feb 6, 2023
Recurrent Refractory Mantle Cell Lymphoma
Recruiting
- Mantle Cell Lymphoma
-
Beijing, Beijing, ChinaPeking University Third Hospital
Aug 1, 2022
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Biospecimen Collection, Follow-Up)
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Biospecimen Collection
- Follow-Up
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)
Not yet recruiting
- Lymphoma, Mantle-Cell
- +7 more
- Zilovertamab
- +2 more
- (no location specified)
Jun 21, 2022
Newly Diagnosed Mantle Cell Lymphoma Trial in Zhengzhou (Rituximab)
Recruiting
- Newly Diagnosed Mantle Cell Lymphoma
-
Zhengzhou, Henan, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzh
Aug 17, 2022
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)
Recruiting
- Follicular Lymphoma
- +4 more
- Obinutuzumab
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Untreated Mantle Cell Lymphoma Trial in Suzhou (zanubrutinib and rituximab, BEAM pretreatment, zanubrutinib maintenance)
Recruiting
- Untreated Mantle Cell Lymphoma
- zanubrutinib and rituximab
- +2 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Aug 16, 2022
"Don't Eat me" Signal in Hematological Malignancies: CD24 as New
Recruiting
- Mantle-cell Lymphoma
- B Cell Chronic Lymphocytic Leukemia
-
Monza, MB, ItalyAndrea Aroldi
May 24, 2023
Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in Madison (Bendamustine, Obinutuzumab)
Recruiting
- Mantle Cell Lymphoma
- +2 more
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Sep 13, 2022
CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive Trial in Atlanta, Johns Creek (Bendamustine, Obinutuzumab, Venetoclax)
Active, not recruiting
- CCND1 Positive
- +2 more
- Bendamustine
- +2 more
-
Atlanta, Georgia
- +2 more
Nov 2, 2022
Mantle Cell Lymphoma Trial in Duarte, Ann Arbor, Columbus (Venetoclax, Lenalidomide, Rituximab)
Active, not recruiting
- Mantle Cell Lymphoma
- Venetoclax
- +2 more
-
Duarte, California
- +2 more
Oct 18, 2022
Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell Trial in United States (ABT-199 and Ibrutinib Combination)
Completed
- Lymphoma, Mantle-Cell
- Recurrent Lymphoma, Mantle-Cell
- ABT-199 and Ibrutinib Combination
-
Duarte, California
- +3 more
May 22, 2022
Mantle Cell Lymphoma, MCL Trial in United States (Tafasitamab, Lenalidomide)
Recruiting
- Mantle Cell Lymphoma
- MCL
-
Basking Ridge, New Jersey
- +6 more
Mar 27, 2023
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma Trial in Duarte
Not yet recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +2 more
- Biopsy
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
May 15, 2023
Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia Trial (Brexucabtagene Autoleucel)
Available
- Mantle Cell Lymphoma
- Acute Lymphoblastic Leukemia
- Brexucabtagene Autoleucel
- (no location specified)
Mar 17, 2023
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma Trial in India (Acalabrutinib capsule)
Active, not recruiting
- Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
- Acalabrutinib capsule
-
Ahmedabad, India
- +12 more
Feb 2, 2023
Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial (Routine care as per
Not yet recruiting
- Chronic Lymphocytic Leukemia (CLL)
- +5 more
- Routine care as per site standard.
- (no location specified)
Sep 15, 2023
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Tampa (Fludarabine, Cyclophosphamide,
Recruiting
- Chronic Lymphocytic Leukemia
- +4 more
- Fludarabine
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Jan 12, 2023
Lymphoma, Mantle Cell Lymphoma Trial in Houston (Acalabrutinib, Rituximab, Brexucabtagene Autoleucel)
Not yet recruiting
- Lymphoma
- Mantle Cell Lymphoma
- Acalabrutinib
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Aug 10, 2022
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,
Not yet recruiting
- Non-hodgkin Lymphoma
- +9 more
- CD79b-19 CAR T cells
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 6, 2023
B-cell Malignancies Undergoing Treatment With Bruton Tyrosine
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +4 more
- Non-Interventional Study
-
Rochester, MinnesotaMayo Clinic in Rochester
Nov 22, 2023
Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)
Recruiting
- Mantle Cell Lymphoma
- Refractory Lymphoma
- Acalabrutinib
- +2 more
-
Boston, Massachusetts
- +1 more
Aug 8, 2022
Mantle Cell Lymphoma Trial in Baltimore (Venetoclax Oral Tablet [Venclexta])
Recruiting
- Mantle Cell Lymphoma
- Venetoclax Oral Tablet [Venclexta]
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jun 29, 2022